Literature DB >> 736633

[Comparative high rising dose study of oral 17-alpha-ethinylestradiol (EE2), estriol (E3), and parenteral 16-alpha-17-beta-estrioldihemisuccinate (E3-suc) in their effects on serum levels of glutamate transaminase (GOT), pyruvate transaminase (GPT), leucine amino peptidase (LAP), alkaline phosphatase (AP), and bilirubin in 30 hysterectomized and ovarectomized women (author's transl)].

D Leis, H Zach, P Kohler.   

Abstract

UNLABELLED: 30 hysterectomized and ovarectomized women were treated with three different estrogens: EE2 orally, E3 orally, and E3-suc intramuscularly. Each patient received one substance over 5 days doubling the dose every consecutive day, and switching to another estrogen after a treatment free interval of 2 days, rising the dosage of the second preparation twofold every consecutive day over another 5 days. Thus, each patient served as her own control with respect to 2 of the 3 tested estrogens. Six groups were required to test all sequences possible. The patients were allocated by random. GOT, GPT, LAP, AP and bilirubin were estimated daily over 2 weeks. The starting dose of EE2 was 0.25 mg, of E3 2 mg, and of E3-suc 2.5 mg.
RESULTS: There were marked elevations of all serum enzymes during the week of EE2 treatment. If EE2 was given in the first week, and either E3 or E3-suc in the second one there was a prompt fall of all enzyme levels in spite of the approximately tenfold higher dose of the latter two estrogens. There were only minor elevations of the enzymes after oral E3 and parenteral E3-suc in some subjects and no differences of response between these two estrogens. Bilirubin reacted with an overall rise in the majority of patients irrespective of the type of estrogen.

Entities:  

Keywords:  Biology; Clinical Research; Endocrine System; Enzymes; Enzymes And Enzyme Inhibitors; Estriol; Estrogens--side effects; Ethinyl Estradiol; Hormones; Physiology; Research Methodology

Mesh:

Substances:

Year:  1978        PMID: 736633     DOI: 10.1007/bf02119224

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  13 in total

1.  Recurrent intrahepatic cholestasis of pregnancy. Report of six cases, and review of the literature.

Authors:  U P Haemmerli; H I Wyss
Journal:  Medicine (Baltimore)       Date:  1967-07       Impact factor: 1.889

2.  Hepatic and renal excretory metabolism of bile salts: a background for understanding steroid-induced cholestasis.

Authors:  A Despopoulos
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

Review 3.  Hormones and the liver. The effect of estrogens, progestins, and pregnancy on hepatic function.

Authors:  C S Song; A B Rifkind; P N Gillette; A Kappas
Journal:  Am J Obstet Gynecol       Date:  1969-11-01       Impact factor: 8.661

4.  Liver dysfunction with mestranol but not with norethynodrel in a patient with Enovid-induced jaundice.

Authors:  E Urban; B W Frank; F Kern
Journal:  Ann Intern Med       Date:  1968-03       Impact factor: 25.391

5.  Biologic actions of some natural steroids on the liver.

Authors:  A Kappas
Journal:  N Engl J Med       Date:  1968-02-15       Impact factor: 91.245

6.  Effect of oral contraceptives on glucuronyl transferase.

Authors:  T Hargreaves; R F Piper; J Cam
Journal:  Nat New Biol       Date:  1971-11-24

7.  Recurrent cholestatic jaundice of pregnancy with demonstrated estrogen sensitivity.

Authors:  M J Kreek; M H Sleisenger; G H Jeffries
Journal:  Am J Med       Date:  1967-11       Impact factor: 4.965

8.  ESTROGEN PHARMACOLOGY. I. THE INFLUENCE OF ESTRADIOL AND ESTRIOL ON HEPATIC DISPOSAL OF SULFOBROMOPHTHALEIN (BSP) IN MAN.

Authors:  M N MUELLER; A KAPPAS
Journal:  J Clin Invest       Date:  1964-10       Impact factor: 14.808

9.  The effect of oral contraceptive steroids on bile secretion and bilirubin Tm in rats.

Authors:  T A Heikel; G H Lathe
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

10.  The effect of estrogen on bile formation in the rat.

Authors:  E L Forker
Journal:  J Clin Invest       Date:  1969-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.